Valneva SEVALNEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.
VALN Q1 FY2023 Key Financial Metrics
Revenue
$36.2M
Gross Profit
$14.1M
Operating Profit
$-17.9M
Net Profit
$-19.6M
Gross Margin
38.9%
Operating Margin
-49.5%
Net Margin
-54.1%
YoY Growth
N/A
Valneva SE Q1 FY2023 Financial Summary
Valneva SE reported revenue of $36.2M for Q1 FY2023, with a net profit of $-19.6M (-54.1% margin). Cost of goods sold was $22.1M, operating expenses totaled $32.0M.
Key Financial Metrics
| Total Revenue | $36.2M |
|---|---|
| Net Profit | $-19.6M |
| Gross Margin | 38.9% |
| Operating Margin | -49.5% |
| Report Period | Q1 FY2023 |
Valneva SE Quarterly Revenue & Net Profit History
Valneva SE results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2023 | $36.2M | — | $-19.6M | -54.1% |
| Q2 FY2022 | $93.2M | — | N/A | N/A |
Income Statement
| Q2 2022 | Q1 2023 | |
|---|---|---|
| Revenue | $93.2M | $36.2M |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2022 | Q1 2023 | |
|---|---|---|
| Assets | $783.1M | $637.2M |
| Liabilities | $682.4M | $416.0M |
| Equity | $100.7M | $221.2M |
Cash Flow
| Q1 2023 | |
|---|---|
| Operating CF | $-26.3M |